Last reviewed · How we verify
NCT00384072
A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
Phase 3 trial testing bazedoxifene BZA-20 in Postmenopause in 500 participants. Completed in 1 September 2007.
Quick facts
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 500 |
| Start date | 1 May 2006 |
| Estimated completion | 1 September 2007 |
| Sites | 20 locations across China, South Korea, Taiwan |
Drugs / interventions tested
- bazedoxifene BZA-20 — full drug profile →
Conditions studied
- Postmenopause — all drugs for Postmenopause →
- Osteoporosis — all drugs for Osteoporosis →
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer — full company profile →
Who can join
45 and older, female only, with Postmenopause or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- The percent change from baseline in lumbar spine bone mineral density (BMD) after 6 months of treatment
Sponsor's own description
The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bazedoxifene for the prevention of postmenopausal osteoporosis.
Gennari L, Merlotti D, De Paola V, Martini G, et al · · 2008 · cited 30× · PMID 19337430 · DOI 10.2147/tcrm.s3476
Verify or expand the search:
- PubMed search for NCT00384072
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postmenopause
Currently open trials in the same condition.
- NCT06813261 — GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women · NA · recruiting
- NCT06951022 — The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women · NA · active not recruiting
Other Wyeth is now a wholly owned subsidiary of Pfizer trials
Trials by the same sponsor.
- NCT00909688 — Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses · Phase 1 · completed
- NCT00853749 — Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine · Phase 3 · completed
- NCT00894634 — Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
- NCT00854009 — Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects · Phase 1 · completed
- NCT00837837 — Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00384072 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wyeth is now a wholly owned subsidiary of Pfizer
- Last refreshed: 19 December 2007
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00384072.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing